01. RETROD at a glance
RETROD is MGMT Research’s name for retatrutide. Our vial options are 10 mg and 20 mg of lyophilized research material. The amount on the label is the total compound in the vial; it is not a sample size or a syringe measurement.
Retatrutide activates three receptor pathways: GLP-1, GIP and glucagon. Published human studies investigate its effects on body weight and metabolic outcomes. Study findings concern the trial material and protocol, and do not establish the identity, purity or suitability of a separately supplied research vial.
02. Before you begin
Start with the vial label, the applicable batch documentation and your laboratory’s approved procedure. Confirm the compound name, quantity, lot identifier and expiry before preparing a sample.
- RETROD 10 mg or 20 mg vial
- Protocol-compatible diluent and a suitable measuring device
- New sterile syringes and needles where required by the procedure
- Alcohol preparation pads, a clean work surface and appropriate protective equipment
- A sharps container and a preparation record
Check the COA & Batch Reports page for the report corresponding to your lot. A pending report is not a completed test result.
03. BAC water: what the label tells you
Our BAC Water product is supplied in a 3 mL vial. Check the container label for its composition, storage conditions and handling instructions. The amount supplied is not automatically the amount to add to a RETROD vial.
Bacteriostatic water contains a preservative, but that does not make a contaminated preparation sterile. A diluent’s expiry also does not establish the stability of a compound mixed with it. Confirm compatibility and the required final volume in the research protocol.
Single-dose and multidose containers have different handling requirements. CDC guidance for opened multidose medication vials is generally 28 days unless the manufacturer specifies otherwise; this is not evidence that a reconstituted RETROD sample remains stable for 28 or 56 days. [2]
04. Reconstitution workflow
Reconstitution means adding the specified diluent to a freeze-dried material to prepare a solution. Follow the supplier’s validated instructions and your laboratory procedure for the actual preparation.
- Identify: verify the vial quantity, lot and diluent.
- Calculate: record the intended final concentration and volume before opening containers.
- Prepare: use a clean designated work area and aseptic technique.
- Mix: use the validated addition and mixing method; do not improvise heating or agitation.
- Inspect and record: document appearance, final volume, preparation date, storage conditions and the protocol-defined use period.
Visible particles, damage or suspected contamination require investigation. A clear solution alone does not prove sterility or potency.
05. 10 mg and 20 mg concentration charts
These are laboratory calculation examples, using a final solution volume of 2 mL. They do not select a human dose or establish a validated mixing procedure. Use the actual final volume specified by your protocol.
| U-100 marking | Volume | 10 mg vial | 20 mg vial |
|---|---|---|---|
| 5 units | 0.05 mL | 0.25 mg | 0.5 mg |
| 10 units | 0.10 mL | 0.5 mg | 1 mg |
| 20 units | 0.20 mL | 1 mg | 2 mg |
| 25 units | 0.25 mL | 1.25 mg | 2.5 mg |
| 50 units | 0.50 mL | 2.5 mg | 5 mg |
| 100 units | 1.00 mL | 5 mg | 10 mg |
Example: 20 mg in a final volume of 2 mL gives 10 mg/mL. A 2 mg laboratory sample occupies 0.20 mL, corresponding to 20 units on a U-100 scale.
Changing the volume changes every conversion. For example, 10 mg in 1 mL and 20 mg in 2 mL both give 10 mg/mL.
06. Understanding mg, mL and syringe units
mg measures compound mass. mL measures liquid volume. U-100 markings represent a volume scale: 100 units correspond to 1 mL. They are not universal “peptide units.”
Sample volume (mL) = sample mass (mg) ÷ concentration (mg/mL)
U-100 marking = sample volume (mL) × 100
Check the scale and capacity of the actual device. Follow its manufacturer’s instructions for reading the plunger position. Do not estimate between markings that the device cannot reliably resolve.
07. What published dosing research actually studied
The 2023 phase 2 obesity trial enrolled 338 adults and studied once-weekly retatrutide at target doses of 1, 4, 8 or 12 mg. The 4 mg and 8 mg groups included different starting-dose regimens; the 12 mg group began at 2 mg. These were monitored study arms, not a universal beginner schedule. [1]
At 48 weeks, mean weight changes were −8.7%, −17.1%, −22.8% and −24.2% in those respective target-dose groups, compared with −2.1% with placebo. These are study averages, not individual promises. [1]
A number falling between studied doses does not automatically make that number an independently tested regimen. Community “beginner,” “intermediate” and “advanced” schedules, split dosing and maintenance routines should not be treated as conclusions of this trial. This guide does not provide a self-administration or dose-escalation plan.
08. Side effects and considerations
In that phase 2 trial, gastrointestinal adverse events were the most common. They were dose-related and generally mild to moderate. Lower starting doses partly reduced these events. Dose-dependent increases in heart rate were also reported. [1]
Trial monitoring and participant eligibility matter when interpreting tolerability. A research guide cannot determine whether a compound, combination or schedule is appropriate for an individual. Questions about personal treatment, missed doses or symptoms belong with a qualified clinician.
09. Storage and preparation records
Follow the storage conditions on the actual product label and the validated procedure for the preparation. Do not transfer a shelf-life claim from another supplier, a different formulation or an unopened diluent to your mixed sample.
Record the compound, lot, mass, diluent, final volume, concentration, preparation date and applicable use-by limit. Without product-specific stability data, this guide cannot assign a 56-day post-mixing shelf life.
Use a new sterile needle and syringe when accessing a vial as required by aseptic practice, keep preparation areas clean, and discard material when sterility is questionable. Dispose of sharps in an appropriate container. [2]
10. Common calculation mistakes
- Using a chart for a different vial quantity.
- Confusing the 3 mL BAC Water supply vial with the final volume of the prepared solution.
- Treating mg and mL as interchangeable.
- Using U-100 conversions with a different syringe scale.
- Changing the diluent volume without recalculating concentration.
- Confusing the number of theoretical samples with a validated storage period.
11. Quick questions
Does a 20 mg vial mean a 20 mg sample?
No. It describes the total compound mass supplied in the vial.
Does adding more water add more compound?
No. It increases volume and reduces concentration; total compound mass remains the same, assuming no preparation losses.
How many 2 mg laboratory samples are in 20 mg?
The theoretical calculation is 20 ÷ 2 = 10 samples, before preparation and transfer losses. It says nothing about how long a preparation can be stored.
Does this guide confirm a batch is tested?
No. Refer to the individual lot’s published report and status in COA & Batch Reports.
12. Glossary and sources
Lyophilized: freeze-dried material.
Reconstitution: preparing a solution from a dry material using an appropriate diluent.
Concentration: compound mass per unit of solution volume.
Aliquot: a measured portion of a sample.
Agonist: a substance that activates a receptor.
COA: certificate of analysis for the identified sample or batch.
Primary references
- Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM, 2023.
- CDC: Preventing Unsafe Injection Practices.
Research context and concentration examples are provided for education. MGMT Research products are for laboratory research only, not for human or veterinary use.
RETROD | How long can I take it? →
↑ Back to top